Sorrento Therapeutics, Inc.

Pipeline Progress: Over 25 New Therapies in Development for Metastatic Liver Cancer

2 months ago

• DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options. • Several promising clinical trials are underway in 2025, including studies evaluating novel combinations such as AK104 plus lenvatinib, tislelizumab with lenvatinib, and triplet therapy of nivolumab, relatlimab and bevacizumab. • Key emerging therapies include exoASO-STAT6 targeting tumor-associated macrophages, STP705 dual TGF-ß1/COX-2 inhibitor, and ONCR-177, an oncolytic viral immunotherapy expressing five transgenes to fight tumors through multiple mechanisms.

Sorrento's License Partner, Lee's Pharm, Announces Full Enrollment in Phase III Trial of Socazolimab for ES-SCLC

3 years ago

Lee's Pharmaceutical Holdings Limited, a subsidiary of Sorrento Therapeutics, has completed the enrollment of 498 patients for a Phase III clinical trial of Socazolimab, an anti-PD-L1 monoclonal antibody, combined with chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). The trial, involving 54 centers across China, is led by Prof. Shun Lu from Shanghai Chest Hospital, with an interim analysis expected in April 2023.